Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data

Susanne Schmitz (), Michel Vaillant, Christell Renoux, Robert L. Konsbruck, Pierre Hertz, Magali Perquin, Lukas Pavelka, Rejko Krüger and Laetitia Huiart
Additional contact information
Susanne Schmitz: Luxembourg Institute of Health
Michel Vaillant: Luxembourg Institute of Health
Christell Renoux: Jewish General Hospital
Robert L. Konsbruck: Caisse Nationale de Santé
Pierre Hertz: Caisse Nationale de Santé
Magali Perquin: Luxembourg Institute of Health
Lukas Pavelka: University of Luxembourg
Rejko Krüger: Centre Hospitalier de Luxembourg (CHL)
Laetitia Huiart: Luxembourg Institute of Health

PharmacoEconomics - Open, 2022, vol. 6, issue 3, No 8, 405-414

Abstract: Abstract Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with an increasing prevalence worldwide. Estimates of the economic burden associated with PD vary widely across existing studies due to differences in setting and study design. The prevalence and cost of care for PD in Luxembourg are currently unknown. Objective The aims of this study were to estimate (1) the prevalence of PD in Luxembourg and (2) the cost of care for PD to the national healthcare insurance based on routinely collected healthcare data. Methods This analysis was based on individual patient-level data collected by the national healthcare insurance in Luxembourg during 2007–2017, which covers over 95% of the resident population. People with PD were identified based on drug reimbursement profiles. Cost of care was estimated according to a comparative analysis of the healthcare resources consumed by people with PD compared with an age- and sex-matched control group. Results We determined a PD prevalence of 928 per 100,000 individuals aged 50 years and older in 2016, higher in men (1032 per 100,000) than in women (831 per 100,000). The total mean cost of care for PD was estimated at €22,673 per patient per year in 2016, with the highest costs being associated with long-term care (69%). Conclusion This was the first attempt to estimate the prevalence and cost of care of PD in Luxembourg. The work demonstrated the usefulness of routinely collected data in Luxembourg for such analyses. Our study confirms the significant burden of PD to the healthcare system, especially on long-term care.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-021-00321-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:6:y:2022:i:3:d:10.1007_s41669-021-00321-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-021-00321-3

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().